Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.99 USD | +1.17% |
|
+1.92% | -15.07% |
06-25 | Arrowhead Pharmaceuticals to Advance Investigational Medicine Plozasiran Into Late-stage Cardiovascular Study | MT |
06-25 | Transcript : Arrowhead Pharmaceuticals, Inc. - Special Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.07% | 3.23B | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- ARWR Stock
- News Arrowhead Pharmaceuticals, Inc.
- Arrowhead Says Potential Obesity Treatment Shows 'Promising' Preclinical Results -- Shares Rise